Search research articles
Contact Us
Filters
Showing results (81-90 of 95) with videos related to
Page
of 10
Sort By:
Cancer Reports (Hoboken, N.J.)
|
May 3, 2021
Resected pancreatic adenocarcinoma: An Asian institution's experience
Kennedy Yao Yi Ng, Edwin Wei Xiang Chow, Bochao Jiang, et al.
Journal of Hepatology
|
April 17, 2022
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
Samuel Chuah, Joycelyn Lee, Yuan Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2020
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Harry Ho Man Ng, Ren Yuan Lee, Siting Goh, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2023
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma
Neslihan Arife Kaya, David Tai, Xinru Lim, et al.
The Lancet. Gastroenterology & Hepatology
|
October 25, 2021
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial
David Tai, Kelvin Loke, Apoorva Gogna, et al.
JCO Precision Oncology
|
July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience
Amanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Nature Communications
|
June 8, 2019
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Cancer Discovery
|
October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D Kim, Debashis Sarker, Tim Meyer, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 95) with videos related to
Sort By:
Page
of 10
Cancer Reports (Hoboken, N.J.)
|
May 3, 2021
Resected pancreatic adenocarcinoma: An Asian institution's experience
Kennedy Yao Yi Ng, Edwin Wei Xiang Chow, Bochao Jiang, et al.
Journal of Hepatology
|
April 17, 2022
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma
Samuel Chuah, Joycelyn Lee, Yuan Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2017
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle, Maeve Lowery, Rachna T Shroff, et al.
Journal for Immunotherapy of Cancer
|
August 28, 2020
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
Harry Ho Man Ng, Ren Yuan Lee, Siting Goh, et al.
Journal for Immunotherapy of Cancer
|
August 16, 2023
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma
Neslihan Arife Kaya, David Tai, Xinru Lim, et al.
The Lancet. Gastroenterology & Hepatology
|
October 25, 2021
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial
David Tai, Kelvin Loke, Apoorva Gogna, et al.
JCO Precision Oncology
|
July 12, 2021
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience
Amanda O L Seet, Aaron C Tan, Tira J Tan, et al.
Nature Communications
|
June 8, 2019
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
Min Thura, Abdul Qader Al-Aidaroos, Abhishek Gupta, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.
Cancer Discovery
|
October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D Kim, Debashis Sarker, Tim Meyer, et al.
Page
of 10